PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $13,810 | -99.9% | 500,000 | -37.5% | 0.43% | -46.0% |
Q1 2022 | $18,946,000 | -55.7% | 800,100 | -36.0% | 0.79% | -31.6% |
Q4 2021 | $42,750,000 | +60.8% | 1,250,000 | -16.7% | 1.16% | +95.0% |
Q3 2021 | $26,580,000 | +1268.0% | 1,500,000 | +1900.0% | 0.60% | +1650.0% |
Q1 2021 | $1,943,000 | -27.5% | 75,000 | -43.6% | 0.03% | -41.4% |
Q4 2020 | $2,681,000 | +3.1% | 133,000 | 0.0% | 0.06% | -7.9% |
Q3 2020 | $2,600,000 | +5.2% | 133,000 | -5.0% | 0.06% | -8.7% |
Q2 2020 | $2,472,000 | – | 140,000 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pharmstandard International S.A. | 750,632 | $7,724,000 | 26.59% |
BVF INC/IL | 2,617,967 | $26,939,000 | 2.37% |
GREAT POINT PARTNERS LLC | 982,449 | $10,109,000 | 1.58% |
Alambic Investment Management, L.P. | 65,128 | $670,000 | 0.53% |
FARALLON CAPITAL MANAGEMENT LLC | 2,243,202 | $23,083,000 | 0.14% |
ALGERT GLOBAL LLC | 44,477 | $458,000 | 0.10% |
Monashee Investment Management LLC | 42,945 | $442,000 | 0.09% |
Tekla Capital Management LLC | 219,042 | $2,254,000 | 0.08% |
Spark Investment Management LLC | 138,800 | $1,428,000 | 0.08% |
OXFORD ASSET MANAGEMENT LLP | 187,653 | $1,904,000 | 0.04% |